Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D9M0KJ
|
|||
Drug Name |
SRF617
|
|||
Drug Type |
Antibody
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
Company |
Surface oncology
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) | Target Info | . | [2] |
BioCyc | UTP and CTP dephosphorylation II | |||
KEGG Pathway | Purine metabolism | |||
Pyrimidine metabolism | ||||
Epstein-Barr virus infection |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04336098) Study of SRF617 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Surface oncology. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.